Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Topaz Pharmaceuticals has received the US Food and Drug Administration (FDA) approval to file a new drug application (NDA) for ivermectin topical cream as a treatment for head lice infestations in children and adults.
Subscribe to our email newsletter
The NDA, submitted on 7 April 2011, includes data from two randomized double blind phase 3 clinical trials that compared 0.5% ivermectin cream with a vehicle control (placebo).
Achieving ‘lice free’ status within 24 hours of application and maintaining it for at least a fortnight after application was the primary efficacy endpoint.
In total, data from seven clinical studies including more than 900 subjects receiving active drug product were included in the NDA submitted to the FDA.
Topaz president and CEO Robert Radie said this filing represents the transition of the company from the development phase as they are now preparing to commercialize their lead product candidate.
"With the potential for our lead product to be the first ivermectin formulation for the treatment of head lice, we believe we can improve the experience individuals and their families have during a head lice infestation," Radie said.